The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of Cardiac Failure

• Publication date

  1997-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1071-9164(97)90022-1PMID 9547437
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Importance of infarct-related artery patency for recovery of left ventricular function and late survival after primary angioplasty for acute myocardial infarction.

  1996cited by this paper
• The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

  1996cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

  1995cited by this paper
• Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia

  1995cited by this paper
• Early versus late congestive heart failure after initially uncomplicated anterior wall acute myocardial infarction.

  1995cited by this paper
• Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease.

  1995cited by this paper
• Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S).

  1995cited by this paper
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

  1994cited by this paper
• Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology.

  1994cited by this paper
• Role of impaired endothelium-dependent vasodilation in ischemic manifestations of coronary artery disease

  1993cited by this paper
• Arteriographic view of treatment to achieve regression of coronary atherosclerosis and to prevent plaque disruption and clinical cardiovascular events.

  1993cited by this paper
• Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction.

  1993cited by this paper
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

  1991cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1988cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1987cited by this paper

• Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.

  2026cites this paper
• Association of LDL-cholesterol with prognosis in patients admitted for acutely decompensated heart failure.

  2025cites this paper
• Prognostic value of lipid parameters among patients with heart failure: A systematic review and meta‐analysis

  2025cites this paper
• Different Associations between Lipid Levels and Risk for Heart Failure according to Diabetes Progression

  2024cites this paper
• The intersection of heart failure and cancer in women: a review

  2024cites this paper
• Statins and Cardiomyocyte Metabolism, Friend or Foe?

  2023cites this paper
• Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Management of the Underlying Etiologies and Comorbidities of Heart Failure

  2023cites this paper
• The AHA/ACC/HFSA 2022 Heart Failure Guidelines: Changing the Focus to Heart Failure Prevention

  2023cites this paper
• Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Management of the Underlying Etiologies and Comorbidities of Heart Failure

  2023cites this paper
• Predictors of left ventricular ejection function decline in young patients with ST-segment elevation myocardial infarction

  2022cites this paper
• Type 2 Diabetes Complicated With Heart Failure: Research on Therapeutic Mechanism and Potential Drug Development Based on Insulin Signaling Pathway

  2022cites this paper
• Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica

  2022cites this paper
• 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

  2022cites this paper
• 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.

  2021cites this paper
• Hydrophilic or Lipophilic Statins?

  2021cites this paper
• Effect of atorvastatin on systolic and diastolic function in patients with heart failure with reduced ejection fraction (HFrEF).

  2021cites this paper
• A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data

  2021cites this paper
• Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence

  2020cites this paper
• When deep learning meets causal inference: a computational framework for drug repurposing from real-world data

  2020cites this paper
• Heart Failure Risk Reduction: Hydrophilic or Lipophilic Statins?

  2020cites this paper
• Heart Failure as a Consequence of Ischemic Heart Disease

  2020cites this paper
• Clinical Pharmacology of Statins: an Update

  2020cites this paper
• Association between hyperlipidemia and mortality after incident acute myocardial infarction or acute decompensated heart failure: a propensity score matched cohort study and a meta-analysis

  2019cites this paper
• Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence

  2019cites this paper
• Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives.

  2019influential citation
• JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure　- Digest Version.

  2019cites this paper
• Medical Therapy for Heart Failure Caused by Ischemic Heart Disease.

  2019cites this paper
• 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

  2019cites this paper
• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.

  2019cites this paper
• Synergistic effects of HMG‐CoA reductase inhibitor and angiotensin II receptor blocker on load‐induced heart failure

  2018cites this paper
• Simvastatin reduces adrenal catecholamine secretion evoked by stimulation of cholinergic nicotinic and angiotensinergic AT1 receptors

  2018cites this paper
• Generación y validación de un modelo predictivo en pacientes con insuficiencia cardiaca aplicable en servicios de urgencias y centros de atención primaria

  2017cites this paper
• Atorvastatin prevents Angiotensin II induced myocardial hypertrophy in vitro via CCAAT/enhancer-binding protein β.

  2017cites this paper
• Клинические рекомендации. Хроническая сердечная недостаточность (ХСН)

  2017cites this paper
• Statine bei Herzinsuffizienz

  2017cites this paper
• Optimisation of pacemaker therapy for cardiac function

  2017cites this paper
• Heart Failure and Hypertension: Importance of Prevention.

  2017cites this paper
• Evolving Use of Natriuretic Peptides as Part of Strategies for Heart Failure Prevention.

  2017cites this paper
• Guía ESC/EAS 2016 sobre el tratamiento de las dislipemias

  2017cites this paper
• 2017 Position Paper of the Italian Society for Cardiovascular Prevention (SIPREC) for an Updated Clinical Management of Hypercholesterolemia and Cardiovascular Risk: Executive Document

  2017cites this paper
• Heart Failure Prevention: Special Considerations for Women

  2016cites this paper
• Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association.

  2016cites this paper
• tatin Therapy Is Associated With Improved urvival in Ischemic and Non-Ischemic Heart Failure

  2016cites this paper
• 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

  2016cites this paper
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

  2016cites this paper
• Screening study for genetic polymorphisms affecting pharmacokinetics of simvastatin

  2016cites this paper
• Contributory risk and Management of Comorbidities of Hypertension, obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure

  2016cites this paper
• Lipophilic Statin Versus Rosuvastatin (Hydrophilic) Treatment for Heart Failure: a Meta-Analysis and Adjusted Indirect Comparison of Randomised Trials

  2016cites this paper
• Screening study for genetic polymorphisms affecting pharmacokinetics of pioglitazone

  2016cites this paper
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention

  2016cites this paper
• [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure].

  2016cites this paper
• Pharmacological role of atorvastatin in myocardium and smooth muscle progenitor cells

  2016cites this paper
• 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

  2016cites this paper
• Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica

  2016cites this paper
• Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies

  2016cites this paper
• Pivotal Cytoprotective Mediators and Promising Therapeutic Strategies for Endothelial Progenitor Cell-Based Cardiovascular Regeneration

  2016cites this paper
• Emerging ole of Statins in the reatment of Heart Failure

  2016cites this paper
• The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials

  2015cites this paper
• Selenium and coenzyme Q10 interrelationship in cardiovascular diseases--A clinician's point of view.

  2015cites this paper
• Are statins failing in heart failure?

  2015cites this paper
• Effects of Statins on Left Ventricular Diastolic Function in Patients with Dyslipidemia and Diastolic Dysfunction (Stat-LVDF Study).

  2015cites this paper
• Stage A Heart Failure Is Not Adequately Recognized in US Adults: Analysis of the National Health and Nutrition Examination Surveys, 2007-2010

  2015cites this paper
• Role of lipids and lipoproteins in myocardial biology and in the development of heart failure

  2015cites this paper
• Intensity of statin therapy and new hospitalizations for heart failure in patients with type 2 diabetes

  2015cites this paper
• Association between use of statins and outcomes in heart failure with reduced ejection fraction: prospective propensity score matched cohort study of 21 864 patients in the Swedish Heart Failure Registry.

  2015cites this paper
• Inflammatory Modulation by Statins and Heart Failure: From Pharmacological Data to Clinical Evidence

  2015cites this paper
• The use of statins in patients with heart failure: more questions than answers.

  2015cites this paper
• Medical Treatment of Heart Failure and Coronary Heart Disease

  2015cites this paper
• Heart failure with preserved ejection fraction: uncertainties and dilemmas

  2015cites this paper
• Rac1-Mediated Effects of HMG-CoA Reductase Inhibitors (Statins) in Cardiovascular Disease

  2014cites this paper
• Statins in heart failure--With preserved and reduced ejection fraction. An update.

  2014influential citation
• TREATMENT OF DYSLIPIDAEMIA: from recommendations to clinical practice

  2014cites this paper
• Statin-Mediated Low-Density Lipoprotein Lowering in Chronic Congestive Heart Failure

  2014cites this paper
• Stage A Heart Failure: Identification and Management of Heart Failure Risk Factors

  2014cites this paper
• Lipids, statins, and clinical outcomes in heart failure: rethinking the data

  2014cites this paper
• Management of ACCF/AHA Stage A and B patients.

  2014cites this paper
• Statins in heart failure: do we need another trial?

  2013cites this paper
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

  2013cites this paper
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cites this paper
• Comparative effects of statins on murine cardiac gene expression profiles in normal mice.

  2013cites this paper
• Lipophilic versus hydrophilic statin therapy for heart failure: a protocol for an adjusted indirect comparison meta-analysis

  2013cites this paper
• Srce i krvni Sudovi

  2013cites this paper
• Task Force on Practice Guidelines Report of the American College of Cardiology Foundation/American Heart Association 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A

  2013cites this paper
• Polimorfizm wybranych genów oraz ich wpływ na występowanie zaburzeń rytmu i rokowanie w przewlekłej niewydolności serca

  2013cites this paper
• 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

  2013cites this paper
• Treatment Strategies for the Prevention of Heart Failure

  2013cites this paper
• Predictors of Recovery of Left Ventricular Systolic Dysfunction after Acute Myocardial Infarction: From the Korean Acute Myocardial Infarction Registry and Korean Myocardial Infarction Registry

  2013cites this paper
• Low-density lipoprotein levels in patients with acute heart failure.

  2013cites this paper
• Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial.

  2013cites this paper
• ACCF/AHA Practice Guideline

  2013cites this paper
• Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).

  2012cites this paper
• Primary Prevention of Heart Failure

  2012cites this paper
• Reporting of Short-Term Clinical Outcomes After Esophagectomy: A Systematic Review

  2012cites this paper
• Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project.

  2012cites this paper
• Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study).

  2012cites this paper
• HMG-CoA Reductase Inhibitors in Chronic Heart Failure

  2012cites this paper
• Synergistic effect of combined HMG-CoA reductase inhibitor and angiotensin-II receptor blocker therapy in patients with chronic heart failure: the HF-COSTAR trial.

  2011cites this paper
• [Atorvastatin induced increase in homologous angiotensin I converting enzyme (ACE2) mRNA is associated to decreased fibrosis and decreased left ventricular hypertrophy in a rat model of diabetic cardiomyopathy].

  2011cites this paper
• Epidemiology and risk profile of heart failure

  2011cites this paper
• Comparison of the effects of dietary flavonoids and statins on lipopolysaccharide-induced vascular inflammation

  2011cites this paper